Does Rallies show Form 4 insider transactions for TVTX?

Yes. Rallies tracks TVTX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is TVTX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TVTX. It does not provide personalized investment advice.

TVTX (Travere Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Travere Therapeutics, Inc. Common Stock (TVTX) is a publicly traded Healthcare sector company. As of May 21, 2026, TVTX trades at $42.86 with a market cap of $3.99B and a P/E ratio of -148.83. TVTX moved +2.91% today. Year to date, TVTX is +14.12%; over the trailing twelve months it is +147.66%. Its 52-week range spans $12.91 to $48.61. Analyst consensus is strong buy with an average price target of $53.42. Rallies surfaces TVTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading TVTX stock inside the company?

Recent TVTX insider activity includes ROTE WILLIAM E. sold 2.76K, REED ELIZABETH E sold 2.08K, Inrig Jula sold 311, Dube Eric M sold 22.50K, and Cline Christopher R. sold 310. Rallies tracks insider transaction dates, shares, prices, and estimated values.

TVTX Key Metrics

Key financial metrics for TVTX
Metric	Value
Price	$42.86
Market Cap	$3.99B
P/E Ratio	-148.83
EPS	$-0.29
Dividend Yield	0.00%
52-Week High	$48.61
52-Week Low	$12.91
Volume	5
Avg Volume	0
Revenue (TTM)	$490.73M
Net Income	$-25.55M
Gross Margin	97.89%

Recent TVTX Insider Trades

ROTE WILLIAM E. sold 2.76K (~$121.43K) on May 6, 2026.
REED ELIZABETH E sold 2.08K (~$91.24K) on May 6, 2026.
Inrig Jula sold 311 (~$13.67K) on May 6, 2026.
Dube Eric M sold 22.50K (~$988.88K) on May 6, 2026.
Cline Christopher R. sold 310 (~$13.62K) on May 6, 2026.

Latest TVTX News

Travere Therapeutics Posts Q1 Sales Surge 64% to $124.5M with FSGS Approval — May 4, 2026
Travere’s Filspari Gains FDA Nod for FSGS, Shares Soar 34.7% — Apr 14, 2026
Travere Gains FDA Approval for FSGS Drug After 46% Proteinuria Drop — Apr 14, 2026
Vertex Achieves 52% Proteinuria Drop in Phase III, Files FDA Submission — Mar 10, 2026
Piper Sandler Lifts Travere Therapeutics Price Target to $38 with 40% Upside — Mar 10, 2026

TVTX Analyst Consensus

13 analysts cover TVTX: 0 strong buy, 12 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $53.42.

Common questions about TVTX

Who is trading TVTX stock inside the company?: Recent TVTX insider activity includes ROTE WILLIAM E. sold 2.76K, REED ELIZABETH E sold 2.08K, Inrig Jula sold 311, Dube Eric M sold 22.50K, and Cline Christopher R. sold 310. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for TVTX?: Yes. Rallies tracks TVTX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is TVTX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TVTX. It does not provide personalized investment advice.